Skip to Content

The Cooper Companies Inc COO Stock Quote

| Rating as of

Morningstar‘s Stock Analysis COO

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Maintaining Cooper's FVE as Shares Appear Fairly Valued

Aaron Degagne Equity Analyst

Business Strategy and Outlook

| Aaron Degagne |

As a cash-pay business with sticky customers and few competitors, the contact lens industry is an attractive market, in our opinion. Four main players (Johson & Johnson, Alcon, Bausch & Lomb, and Cooper) dominate the global market, and industry regulations paired with specialized manufacturing and technological ability creates strong barriers to entry, keeping new entrants away.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics COO

Company Profile COO

Business Description

Cooper Companies operates two units: CooperVision and CooperSurgical. Accounting for approximately 75% of total sales, CooperVision is the the second-largest player in the oligopolistic contact lens market. Over 50% of CooperVision's sales are in international territories. The second unit, CooperSurgical, develops and manufactures diagnostic and surgical products for gynecologists and obstetricians, including the Paragard IUD, which Cooper acquired from Teva in 2017.

Contact
6101 Bollinger Canyon Road, Suite 500
San Ramon, CA, 94583
T +1 925 460-3600
Industry Medical Instruments & Supplies
Most Recent Earnings Apr 30, 2022
Fiscal Year End Oct 31, 2021
Stock Type Classic Growth
Employees 12,000